Drug Profile
Foralumab - Tiziana Life Sciences
Alternative Names: NI-0401; NI-0401/α-CD3; TZLS-401Latest Information Update: 10 Jan 2024
Price :
$50
*
At a glance
- Originator Medarex; NovImmune SA
- Developer Light Chain Bioscience; NovImmune SA; Tiziana Life Sciences
- Class Anti-inflammatories; Antidementias; Antihaemorrhagics; Antihyperglycaemics; Hepatoprotectants; Monoclonal antibodies
- Mechanism of Action CD3 antigen inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Crohn's disease; Multiple sclerosis
- Preclinical Alzheimer's disease; Amyotrophic lateral sclerosis; Haemorrhage; Type 1 diabetes mellitus
- No development reported Cytokine release syndrome; Non-alcoholic steatohepatitis; Primary biliary cirrhosis; Type 2 diabetes mellitus
- Discontinued Transplant rejection
Most Recent Events
- 08 Jan 2024 Efficacy data from an expanded access program in Multiple sclerosis released by Tiziana Life Sciences
- 05 Jan 2024 Tiziana Life Sciences files for patent protection for foralumab and GLP-1ra combination therapy
- 28 Dec 2023 No recent reports of development identified for phase-I development in Cytokine release syndrome(Combination therapy) in Brazil (Intranasal)